Wolpin B, Hong D, Spira A, Starodub A, Park W, Sommerhalder D, Valerin J, Barve M, Punekar S, Pelster M, Herzberg B, Azad N, Aung K, Hecht J, Cheng L, Vora R, Salman Z, Zhang Y, Lin T, Garrido-Laguna I. 514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). European Journal Of Cancer 2024, 211: 114992. DOI: 10.1016/j.ejca.2024.114992.Peer-Reviewed Original Research